Specialty Pharmacy

This is the first webcast series from the Crohn's & Colitis Foundation of America targeted to health care professionals.

Video from the National Multiple Sclerosis Society with the message, "MS Kills Connection. Connection Kills MS."

Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.

A new study revealed that lower doses of Velcade (bortezomib), melphalan (Alkeran) and prednisone (VMP) was effective and safe in extending overall and progression-free survival in older patients.

Representatives from The Dana –Farber Cancer Institute, Mount Sinai, and GNS Healthcare recently announced they are teaming up to pool their data and technology assets in order to build a predictive model of multiple myeloma disease progression.

This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.

This video summarizes the research findings from ECTRIMS 2012.

EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced today that the FDA approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

Looking for mobile apps relevant to your specialty business? Here are 7 recommendations from the editors of Specialty Pharmacy Times.

Clinical pathway programs in oncology will be utilized with more frequency in the coming years and may be instrumental in changing prescribing behavior, according to researchers from Decision Resources.

2 major HIV provider groups recently sent pharmaceutical companies and manufacturers a statement urging them to make their antiretrovirals more accessible to patients.

Adam J. Fein, PhD, discussed how wholesaler strategies must change in order to navigate an evolving drug channel infrastructure at the recent 8th Annual Trade and Channel Strategies Conference.

FDA granted accelerated approval to Iclusig (ponatinib) for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

Aetna and Cardinal Health Specialty Solutions announced today an evidence-based program designed to improve cancer care in Michigan.

Commercial health plans have recently started limiting the use of manufacturer copay cards to encourage formulary compliance. The question remains-how will Medicare handle these coupons?

The FDA today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

The deal with GlaxoSmithKline to develop an MD Anderson discovery draws on the expertise of the Institute for Applied Cancer Science.

There have been significant increases in the cost of antiretroviral therapies (ART) for individual therapies and in the cost of therapy initiation over the past several years.

The adoption of clinical pathways helps to standardize the cancer care process, and this practice is becoming increasingly popular.

Rapid growth, expanding specialty drug market propel hiring at nation's largest privately held specialty pharmacy.

The new Indianapolis facility will support Catamaran's win of the $60 million, 6-year State of Indiana Medicaid contract.

Diplomat Specialty Pharmacy and Exelixis, Inc announced today that Diplomat Specialty Pharmacy has been selected as the exclusive specialty pharmacy for Cometriq (cabozantinib).

Connexus Technology recently announced it has been recognized as the 2012 Health Care Innovation Consultant of the Year by the Philadelphia Business Journal and presenting sponsor United Healthcare.

Novo Nordisk announced the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events.

By prescribing clinically similar luteinizing hormone–releasing hormone agonists for the treatment of prostate cancer, Medicare could have saved 13% of its total budget for monthly injections, according to a study from the Office of the Inspector General.